Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00259870 · ClinicalTrials.gov registry record · Phase 2
SB-773812 Administered In Adults With Schizophrenia
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 338
- Enrollment target
NCT00259870 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 338 participants.
The verdict
NCT00259870, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 338 participants
- Enrollment target
Study Summary
This is a two part study designed to evaluate the safety and efficacy of SB-773812 in the treatment of acute schizophrenia. Subjects with acute schizophrenia will be randomized in an adaptive design study to receive placebo, SB-773812 60mg or olanzapine 15mg for 12 weeks in Part A. An interim analysis will be conducted to assess the efficacy and safety of the SB-773812 60mg dose compared with placebo. Based on these data, up to two further doses of SB-773812 will be added to the randomization for Part B.
Interventions
- DRUG Olanzapine
- DRUG SB-773812
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 338 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00259870
The ClinicalTrials.gov registry entry for NCT00259870 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 338 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Olanzapine is the first listed.
NCT00259870 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00259870 about?
NCT00259870 is a clinical study titled "SB-773812 Administered In Adults With Schizophrenia". This is a two part study designed to evaluate the safety and efficacy of SB-773812 in the treatment of acute schizophrenia. Subjects with acute schizophrenia will be randomized in an adaptive design study to receive placebo, SB-773812 60mg or olanzapine 15mg for 12 weeks in Part A. An interim analys...
What is the current status of trial NCT00259870?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 338 participants. The study started on 2005-09. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00259870?
The interventions under investigation include: Olanzapine (DRUG), SB-773812 (DRUG).
Who is sponsoring clinical trial NCT00259870?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.